0001209191-20-027143.txt : 20200505
0001209191-20-027143.hdr.sgml : 20200505
20200505163504
ACCESSION NUMBER: 0001209191-20-027143
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200501
FILED AS OF DATE: 20200505
DATE AS OF CHANGE: 20200505
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sacks Natalie
CENTRAL INDEX KEY: 0001683811
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 20849450
MAIL ADDRESS:
STREET 1: C/O ADURO BIOTECH, INC.
STREET 2: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001708493
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473458693
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-7400
MAIL ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-01
0
0001708493
Harpoon Therapeutics, Inc.
HARP
0001683811
Sacks Natalie
C/O HARPOON THERAPEUTICS, INC.
131 OYSTER POINT BOULEVARD, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
2020-05-01
4
M
0
5826
2.12
A
51580
D
Common Stock
2020-05-01
4
S
0
5826
12.0668
D
45754
D
Employee Stock Option (right to buy)
2.12
2020-05-01
4
M
0
5826
0.00
D
2028-10-17
Common Stock
5826
168926
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Represents the weighted average sales price per share. The shares sold at prices ranging from $11.81 to $12.31 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
/s/ Natalie Sacks by Christopher Whitmore, Attorney-in-Fact
2020-05-05